+ Watch ATHX
on My Watchlist
1. Recent regulatory changes to accelerate regenerative medicine use in Japan, will allow faster development of their products. CEO has already made several trips so as to get his ducks in a row.2.Second quarter results on phase II study on Ulcerative Colitis done by Pfizer using ATHX's their multistem cells.3. Mid year results on the use of multistem on a phase II study in the use of the cells for the treatment of ischemic stroke a potential 20 billion market.
A bunch of catalysts will propel this company. Rulings in Japan have taken the lid off.
ATHX is a very interesting bet in my opinion, because of the impact their product has of changing the medical world and treatments as we know it. I've been struggling with whether 3D printing might have a profound effect in the medical world also, and though I think 3D printing will be a game changer in other areas and hold DDD stock, I think the path that ATHX is on with their stem cell product is better and much more pratical in the short term and long term due to the moral, ethical, and legal complications that will be associated with 3D printing in the medical field. The product that ATHX is and has been working on is truly a remarkable product that has endless possibilities of transforming medical science and the curing of devistating diseases as we know it and as long as the company plan continues on it's course I plan to be invested. In fact, as of now, if I had only 1 choice od what stock to own this would be my pick. Next bump up should be around April when the ongoing trials finish up, and Japan looks to be the first area of opportunity to put their product to use. I've been invested and following ATHX for over a year and never have been as excited about a stock as this one. I see years of growth in the future as new opportunities to expand the usage of their system become available. As a note, due to the type of system they are using, there should not be the moral or ethical questions related to the stem cell therapy they propose. I'm in for the long haul as I see this becoming a 1000 bagger in the future.
High risk but also potential 10 banger in 15 yrs
With them heading into stage II in either 1Q/2Q of 2014, everything looks promising, so definitely in it for the long run.
20 mil in R&D in 2012
Good up and coming product line in the works.
Inflammatory bowel disease Ph 2 results in fall 2013; stroke (HUGE market) Ph 2 in Q2 2014. At 85M market cap, if any of those programs work, this will be more than a 10-bagger.
Great place to park speculative money. Anything stem cell has sex appeal that could really pop on positive news. Partnership with PFE says a lot about the science behind this company and so far management seems very savvy about locking up patents and forming strategic partnerships. This is my BIG speculative play.
Connection to Pfizer shows legitimacy. Management is top notch and patents for stem cell research puts this Athersys in a great position to do well for a long time.
Waiting patiently for a very successful clinical trial to see a big jump. Long term game, this small company is ran by expert-in-field scientific talent and very likely to strike a home-run
This is a real money stock as well, purchased right around this amount very recently.Their flagship product, MultiStem, appears to have application in a wide range of areas, from leukemia to stroke. The Phase I trials are complete, and the product has been pretty successful in stroke victims. The fact that it's efficacy is compromised by how soon it can administered to the stroke victim makes little impact. ALL interventions with stroke victims lose efficacy over time.However, the positive results have so far only been seen in animals. The company will probably need to raise further capital. If you can tolerate high risk, consider adding Athersys (it's my highest risk stock in my real life portfolio).
As of December 2010, Athersys is a speculative stock due to the small revenues, continued losses, and potential share dilution. With a market cap of under $50M, a share price of roughly $2.50 and 70K share per day trading volume, I think this one has been off of wall street's radar. On the other hand, I think Athersys is a small gem of a company that has lots of potential. Athersys has no debt, and roughly $15M in cash as of their last 10Q. Of most interest to me is their Multistem product. They have had success with their multistem product for acute myocardial infarction and for stroke in animal models, but no conclusive statistically valid testing has been done in humans yet. So far the results are limited (Phase I), but have been promising to date even though it is still in the early stages. The multistem product is a biologic product manufactured from stem cells. It is somewhat unique in the stem cell area because it acts more like a drug in that it is administered through an IV or catheter and is flushed from the body naturally. The stem cells are derived from adult stem cells (i.e. bone marrow from a qualified donor) and does not involve embryonic stem cells. From one acceptable donor, Athersys is able to create hundreds of thousands of doses of the product. The product also has a shelf life of 4 years. The product does not require the use of immune suppressive drugs or tissue matching between donor and recipients and it has a consistent safety profile. Current applications of multistem are being pursued in the areas of inflammatory bowel disease (partnered with Pfizer), stroke and acute myocardial infarction (partnered with Angiotech). In AMI (i.e. heart attack), multistem is designed as a supplement to the current standard of care and not a replacement. Management has been effectively utilizing partnerships at both the university and commercial level to help with development from both a cost and capability standpoint while maintaining a reasonable cash burn rate to date. They have also been very conscious of working with the FDA to develop a strong safety profile for their product which may be leveraged in the future if they try to extend the application of the product to different areas and to allay any safety concerns the FDA may have. I think the current share price already prices in some future share dilution.
Product appears commercially viable and already has a nice partnership agreement. Upcoming presentation of phase I data in heart patients should provide a nice boost, and an opportunity to gauge interest from other partners.
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions